Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00747929 · ClinicalTrials.gov registry record · Phase 2
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet
A Phase 2 study, sponsored by Shionogi.
- Completed
- Registry status
- Phase 2
- Development phase
- 724
- Enrollment target
NCT00747929: Completed Phase 2 study, sponsored by Shionogi.
NCT00747929 is a Phase 2 study that has completed, run by Shionogi. The registered enrollment target is 724 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (444% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00747929, a Phase 2 study, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 724 participants
- Enrollment target
Study Summary
1. To evaluate the effect of S-2367 on body weight when administered following a 6-week placebo lead-in period and then a 54-week 800 kilocalorie deficit reduced calorie diet compared to placebo in healthy obese male and female subjects 2. To evaluate the safety and tolerability of S-2367 during 54 weeks of drug exposure 3. To evaluate the steady-state/trough pharmacokinetics of S-2367
Primary Outcome
body weight at 54 weeks compared to body weight at start of treatment
Interventions
- DRUG S-2367 Placebo
- OTHER Reduced Calorie Diet
- DRUG S-2367 800 mg
- DRUG S-2367 1600 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 724 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
What the finished NCT00747929 record still lists
NCT00747929 is an interventional study that assigns participants to a tested intervention. The registered 724 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (444% higher).
The record links to 0 conditions, and to 4 interventions - of which S-2367 Placebo is the first listed.
NCT00747929 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00747929 about?
NCT00747929 is a clinical study titled "Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet". 1. To evaluate the effect of S-2367 on body weight when administered following a 6-week placebo lead-in period and then a 54-week 800 kilocalorie deficit reduced calorie diet compared to placebo in healthy obese male and female subjects 2. To evaluate the safety and tolerability of S-2367 during 54 ...
What is the current status of trial NCT00747929?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 724 participants. The study started on 2007-06. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00747929?
The interventions under investigation include: S-2367 Placebo (DRUG), Reduced Calorie Diet (OTHER), S-2367 800 mg (DRUG), S-2367 1600 mg (DRUG).
Who is sponsoring clinical trial NCT00747929?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00747929's enrollment target sits among peer trials
724 45th of 2000 higher than 1,956 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06664619 · 724 participants · Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
- NCT05634967 · 725 participants
Kesimpta (Ofatumumab) Pregnancy Registry
- NCT06641466 · 723 participants · Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
- NCT07088068 · 723 participants · Phase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia